Pharminent · Daily Brief
November 9, 2026
Regulatory & Approvals
China’s NMPA approves Bio-Thera’s BAT2506 for arthritis indications
China’s NMPA has granted marketing authorization to Bio-Thera Solutions’ BAT2506 for the treatment of ankylosing spondylitis and rheumatoid arthritis.
Pharmaceutical Technology →
Clinical Data
Novartis’ pelacarsen cardiovascular outcomes trial data released
Novartis has revealed data from its cardiovascular outcomes trial of the Lp(a)-targeting drug pelacarsen, which failed, according to Pharmaphorum. Cardiologists were reported to be puzzled by the results.
Pharmaphorum →$NVS
Nkarta reports first human data for NK cell therapy in autoimmune disease
Nkarta will present initial clinical data for its natural killer cell therapy in myositis and systemic sclerosis at the American College of Rheumatology annual meeting in Orlando this week, showing safety and signs of efficacy.
MedCity News →
Deals & Partnerships
argenx to buy Unnatural Products in deal worth up to $1.15B
argenx has agreed to acquire macrocyclic peptide drug developer Unnatural Products for $550 million upfront, in a deal worth up to $1.15 billion. It is argenx’s second acquisition of the year.
Pharmaphorum →
Network Bio and Duke University partner on AI disease models
Network Bio has entered a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.
Pharmaceutical Technology →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.